Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

A socio-ecological model of the management of leprosy reactions in Indonesia and India using the experiences of affected individuals, family members and healthcare providers.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101088677 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6963 (Electronic) Linking ISSN: 14726963 NLM ISO Abbreviation: BMC Health Serv Res Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : BioMed Central, [2001-
    • الموضوع:
    • نبذة مختصرة :
      Background: Leprosy reactions (LR) are immune-mediated complications of leprosy that may be associated with severe and irreversible nerve damage. Non-medical aspects, such as financing, service provision, and healthcare resources in the management of LR are generally overlooked as studies tend to concentrate on clinical features and treatment. Barriers to accessing care and services are a major cause of suboptimal care for people with leprosy. This study aims to explore the barriers to and facilitators of high-quality care and management of LR in two leprosy-endemic countries with different health care models - Indonesia and India - and identify areas for improvement.
      Methods: A socio-ecological model was adopted. Data were obtained from 66 interviews with individuals who experienced LR and were seeking care at the two study sites. In addition, immediate family members of individuals with LR and healthcare workers attending to people with leprosy participated in seven focus group discussions (FGDs).
      Results: This study highlights the significant impact of public health insurance regulations and uptake at the macrosystem level on the provision of healthcare services, clinical decision-making, care expenditure, and the psychological well-being of individuals with LR in Indonesia and India. Lack of specialized health professionals and communication challenges were identified in both study populations. Indonesian participants encounter additional challenges due to a fragmented information system and drug shortages. This study identifies key facilitators in providing high-quality care for LR-affected individuals, including financial assistance, availability of corticosteroid alternatives, timely provision of care, and counselling. It found that the high coverage of public health insurance cards in the Indonesian model has increased access to care among individuals affected by LR, despite the challenges. Conversely, the Indian model of care offers treatment subsidies. The advantage of the Indonesian model is its ability to provide wider access to high-quality care, whereas the Indian model focuses on those in most need. This study emphasizes the importance of addressing these challenges through improved communication strategies, education aimed at the affected individuals, and accessible medical care. Furthermore, variations in care-seeking behaviour and self-care practices were observed in both sites, underscoring the need for culturally sensitive and comprehensive approaches to the management of LR.
      Conclusion: The study findings demonstrate that the factors identified at the four systemic levels are interrelated and have an impact on the access, acceptability, and management of LR services. Despite its accessibility and wider coverage of public health insurance, the integrated service model in Indonesia faces challenges associated with complex regulations and the availability of medication. India's care model offers intensive, specialised care but has difficulties in ensuring sufficient health personnel, resources, and public health insurance coverage. These findings highlight the need to address these challenges to ensure timely, effective, and comprehensive care for individuals with LR.
      Competing Interests: Declarations. Ethics approval and consent to participate: This study followed the Declaration of Helsinki to ensure respect for all participants and protect their health and rights [109]. Three ethical review committees approved this study: Dr. Soetomo General Academic Hospital (070/91/301.4.2/Litb/II/2019), the Leprosy Mission Trust India (5/vii/C-37), and the London School of Hygiene and Tropical Medicine (17007). Before data collection, all participants were given a verbal explanation of the nature and purpose of the research. The participants were informed of the protocol and the consent was then obtained. Participants were informed that interview or FGD questions focused on the issues they encountered during the provision of care and may elicit unpleasant memories. Participants were also informed of their right to not answer questions and leave the study at any moment without explanation. Participants signed a consent form, and approval of minors’ responsible adult was sought. Individuals gave verbal consent if they were unable to provide written consent for any reason, such as illiteracy or physical impairments that prevented them from writing, and the researcher noted it in writing before the start of the interview. A witness, such as the research assistant or a family member of the participant, observed this discussion and signed the consent form after ensuring that the participant fully understood their rights and risks. The researcher’s affiliation with the hospital in Indonesia might have influenced the willingness of participants to openly share any negative experiences. Participants might have been concerned that sharing negative feedback could affect their care or work at the hospital. Despite the consent form stating that participation was voluntary and that participants could withdraw at any time without repercussions, they still had the right to decline to answer any questions that made them uncomfortable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
      (© 2025. The Author(s).)
    • References:
      PLoS Negl Trop Dis. 2013;7(3):e2089. (PMID: 23505585)
      Lepr Rev. 2002 Jun;73(2):123-9. (PMID: 12192968)
      Am J Trop Med Hyg. 2006 May;74(5):868-79. (PMID: 16687695)
      PLoS Negl Trop Dis. 2015 Jun 01;9(6):e0003818. (PMID: 26029928)
      Health Policy Plan. 2023 Mar 16;38(3):289-300. (PMID: 36478057)
      BMC Health Serv Res. 2022 Apr 25;22(1):549. (PMID: 35468797)
      Lepr Rev. 2006 Mar;77(1):25-33. (PMID: 16715687)
      Public Health Nutr. 2013 Jun;16(6):1101-8. (PMID: 22014870)
      AIDS Behav. 2017 Aug;21(8):2412-2438. (PMID: 28631228)
      BMJ. 1998 Aug 29;317(7158):579-82. (PMID: 9721116)
      BMC Health Serv Res. 2017 Sep 29;17(1):684. (PMID: 28962564)
      Adm Policy Ment Health. 2021 Mar;48(2):290-298. (PMID: 32728991)
      Arq Neuropsiquiatr. 2008 Dec;66(4):861-7. (PMID: 19099126)
      Lepr Rev. 2017 Mar;88(1):2-22. (PMID: 30188085)
      Ochsner J. 2010 Spring;10(1):38-43. (PMID: 21603354)
      J Infect Dis. 1993 Aug;168(2):408-14. (PMID: 8335978)
      Health Policy Plan. 2017 Apr 1;32(3):366-375. (PMID: 28365754)
      J Clin Nurs. 2020 Sep;29(17-18):3527-3540. (PMID: 32564410)
      JAMA. 2025 Jan 7;333(1):71-74. (PMID: 39425955)
      Lepr Rev. 2008 Dec;79(4):372-86. (PMID: 19274984)
      Int J MCH AIDS. 2015;3(1):85-95. (PMID: 27621990)
      PLoS One. 2021 Feb 5;16(2):e0246602. (PMID: 33544761)
      Lepr Rev. 2009 Mar;80(1):65-76. (PMID: 19472853)
      Lepr Rev. 2002 Jun;73(2):111-22. (PMID: 12192967)
      PLoS Negl Trop Dis. 2017 Jul 13;11(7):e0005725. (PMID: 28704363)
      PLoS Negl Trop Dis. 2012;6(6):e1702. (PMID: 22745841)
      PLoS Negl Trop Dis. 2015 Sep 09;9(9):e0004065. (PMID: 26351858)
      BMC Med Inform Decis Mak. 2008 Oct 06;8:45. (PMID: 18837999)
      BMJ. 2016 Sep 23;354:i4803. (PMID: 27662893)
      PLoS Negl Trop Dis. 2022 Apr 8;16(4):e0010264. (PMID: 35394998)
      Int J Lepr Other Mycobact Dis. 1992 Jun;60(2):173-84. (PMID: 1522359)
      PLoS One. 2017 Jul 20;12(7):e0181421. (PMID: 28727833)
      PLoS One. 2009 Dec 18;4(12):e8351. (PMID: 20020051)
      PLoS Negl Trop Dis. 2017 Jul 3;11(7):e0005716. (PMID: 28671966)
      PLoS Negl Trop Dis. 2013 Oct 03;7(10):e2440. (PMID: 24098819)
      Vaccines (Basel). 2021 May 24;9(6):. (PMID: 34073757)
      PLoS Negl Trop Dis. 2019 Apr 5;13(4):e0007302. (PMID: 30951526)
      Int J Lepr Other Mycobact Dis. 2004 Dec;72(4):448-56. (PMID: 15755199)
      JAMA Dermatol. 2019 Oct 01;155(10):1120-1128. (PMID: 31389998)
      PLoS Negl Trop Dis. 2020 Oct 9;14(10):e0008678. (PMID: 33035210)
      PLoS Negl Trop Dis. 2022 Jun 13;16(6):e0010476. (PMID: 35696438)
      Lepr Rev. 2000 Sep;71(3):318-24. (PMID: 11105490)
      PLoS Negl Trop Dis. 2016 Oct 12;10(10):e0005059. (PMID: 27732610)
      Lancet Reg Health Southeast Asia. 2023 Apr 05;13:100180. (PMID: 37383549)
      Trop Med Int Health. 2006 Mar;11(3):268-78. (PMID: 16553906)
      J Gen Intern Med. 1999 Jan;14 Suppl 1:S34-40. (PMID: 9933493)
      Int J Lepr Other Mycobact Dis. 1995 Sep;63(3):422-9. (PMID: 7594926)
      Trans R Soc Trop Med Hyg. 2008 Apr;102(4):329-37. (PMID: 18313706)
      Glob Health Action. 2017 Jan - Dec;10(sup2):1360550. (PMID: 28853325)
      Mem Inst Oswaldo Cruz. 2013 Nov;108(7):901-8. (PMID: 24271045)
      PLoS One. 2019 Feb 6;14(2):e0210955. (PMID: 30726259)
      Heliyon. 2021 Sep 25;7(9):e08068. (PMID: 34632140)
      An Bras Dermatol. 2012 Jan-Feb;87(1):26-35. (PMID: 22481648)
      PLoS Negl Trop Dis. 2020 Dec 31;14(12):e0008973. (PMID: 33382692)
      PLoS Negl Trop Dis. 2020 Aug 6;14(8):e0008329. (PMID: 32760161)
      Cad Saude Publica. 2003 Nov-Dec;19(6):1567-81. (PMID: 14999324)
      PLoS Negl Trop Dis. 2017 Feb 21;11(2):e0005396. (PMID: 28222139)
      Clin Infect Dis. 2007 Jan 1;44(1):33-40. (PMID: 17143812)
      Int J Lepr Other Mycobact Dis. 1995 Mar;63(1):1-7. (PMID: 7730703)
      PLoS Negl Trop Dis. 2022 Sep 6;16(9):e0010756. (PMID: 36067195)
      J Community Health. 2008 Dec;33(6):395-406. (PMID: 18594953)
      J Trop Med. 2013;2013:507034. (PMID: 23577037)
      J Agromedicine. 2017;22(4):298-303. (PMID: 28762886)
      PLoS Negl Trop Dis. 2009 Aug 11;3(8):e500. (PMID: 19668358)
      PLoS Negl Trop Dis. 2016 Dec 13;10(12):e0005088. (PMID: 27959932)
      PLoS Negl Trop Dis. 2015 Jan 15;9(1):e0003431. (PMID: 25590638)
      Ostomy Wound Manage. 1998 Apr;44(4):22, 24-5. (PMID: 9611603)
      Bull World Health Organ. 2000;78(6):717-31. (PMID: 10916909)
      Br Med Bull. 2006;77-78:103-21. (PMID: 17090777)
    • Grant Information:
      706.18.45 Leprosy Research Initiative; 706.18.45 Leprosy Research Initiative; 706.18.45 Leprosy Research Initiative; 706.18.45 Leprosy Research Initiative; 706.18.45 Leprosy Research Initiative; 706.18.45 Leprosy Research Initiative
    • Contributed Indexing:
      Keywords: Delivery of healthcare services; India; Indonesia; Management of leprosy reactions; Person-centred care; Universal health coverage
    • الموضوع:
      Date Created: 20250203 Date Completed: 20250203 Latest Revision: 20250206
    • الموضوع:
      20250206
    • الرقم المعرف:
      PMC11792248
    • الرقم المعرف:
      10.1186/s12913-025-12340-5
    • الرقم المعرف:
      39901142